Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-10,363
Closed -$675K 1440
2025
Q2
$675K Sell
10,363
-2
-0% -$120 ﹤0.01% 1119
2025
Q1
$640K Buy
10,365
+1,836
+22% +$122K ﹤0.01% 1110
2024
Q4
$615K Sell
8,529
-389
-4% -$30.4K ﹤0.01% 1110
2024
Q3
$725K Buy
+8,918
New +$713K ﹤0.01% 1041
2023
Q3
Sell
-11,159
Closed -$904K 1407
2023
Q2
$904K Sell
11,159
-28,241
-72% -$2.31M ﹤0.01% 889
2023
Q1
$3.18M Sell
39,400
-534
-1% -$43K 0.01% 593
2022
Q4
$2.99M Sell
39,934
-4,509
-10% -$321K 0.01% 587
2022
Q3
$2.87M Buy
44,443
+500
+1% +$34.6K 0.01% 571
2022
Q2
$3.04M Sell
43,943
-986
-2% -$73.2K 0.01% 573
2022
Q1
$3.45M Buy
44,929
+4,989
+12% +$359K 0.01% 589
2021
Q4
$3.06M Buy
39,940
+26,579
+199% +$1.95M 0.01% 615
2021
Q3
$986K Buy
13,361
+3,875
+41% +$291K ﹤0.01% 810
2021
Q2
$633K Buy
9,486
+618
+7% +$41.3K ﹤0.01% 879
2021
Q1
$660K Sell
8,868
-57
-0.6% -$4.33K ﹤0.01% 806
2020
Q4
$650K Buy
8,925
+5,952
+200% +$420K ﹤0.01% 746
2020
Q3
$198K Buy
+2,973
New +$188K ﹤0.01% 824

Other funds holding HOLX

VanEck Associates's HOLX Position: Q3 2025 in Review

VanEck Associates sold out of Hologic (HOLX) in Q3 2025, closing a stake of 10,363 shares — an estimated $675K sold.

VanEck Associates first reported a position in HOLX in Q3 2020 and held it in 16 quarters. The position peaked at $3.45M in Q1 2022. 739 funds tracked by Wall St. Rank hold HOLX as of Q3 2025.

  • VanEck Associates reported no remaining Hologic position as of Q3 2025 after selling out during the quarter.
  • VanEck Associates sold 10,363 Hologic shares in Q3 2025, an estimated $675K.
  • VanEck Associates first reported a position in Hologic in Q3 2020 and held it in 16 quarters.
  • VanEck Associates's Hologic position peaked at $3.45M in Q1 2022.
  • 739 funds tracked by Wall St. Rank held Hologic as of Q3 2025.

Based on VanEck Associates's 13F filing for Q3 2025, filed 13 Nov 2025.